Many cancers and chronic infectious diseases actively evade and suppress the immune system. On a molecular level, this evasion is due in part
to the interactions between the proteins PD-1 and B7-H1. In collaboration with GlaxoSmithKline, Amplimmune is developing AMP-224, a fusion
protein that blocks the interaction between PD-1 and B7-H1, for the treatment of cancer and chronic infections. AMP-224 works to overcome
immune suppression, thereby allowing the immune system to fight successfully against cancer and chronic infections.
In collaboration with Daiichi Sankyo, Amplimmune is developing AMP-110 for the treatment of autoimmune diseases. AMP-110 targets T-cells
and elicits a coinhibitory signal that suppresses T cell responses. AMP-110 reduces proliferation of key inflammatory cells, including TH1 and
TH17, and decreases expression of pro-inflammatory cytokines.
The PD-1 pathway is clinically validated and an important target for the treatment of cancer, as well as potentially infection. Amplimmune is leveraging
its translational capabilities to rapidly advance a unique and mechanistically differentiated anti-PD-1 antibody. By combining its immunology
expertise along with a comprehensive biologics development infrastructure, Amplimmune is well positioned to develop a best-in-class anti-PD-1 antibody
and move this program efficiently through clinical proof-of-mechanism. An IND filing for the first candidate is expected in 2013. This program is